1. What are the differences between various antibody discovery platforms?

Different antibody discovery platforms vary mainly in how B cells are sourced, how antibodies are screened. Hybridoma technology: Uses immunized animals and fuses B cells with myeloma cells to generate stable antibody-producing clones. It is reliable and well-established but relatively time-consuming and lower throughput. Single B cell screening platforms: Directly isolate antigen-specific B cells and obtain paired heavy and light chain sequences. This approach is faster, higher throughput, and preserves natural antibody pairing, enabling rapid discovery of functional antibodies. Display technologies (e.g., Phage Display, yeast or mammalian display): Use large in vitro libraries to screen antibodies against targets. They provide very large diversity and do not require immunization, but may require additional steps to optimize affinity and functionality.

2. How should we select the most appropriate antibody discovery platform?

Selection depends on project goals, timeline, and target characteristics. Factors to consider include Diversity Needed, Timeline, Natural Pairing, Species, and Throughput. Hybridoma provides moderate diversity, slower timeline, natural pairing, limited species, and low throughput. Display technologies provide high diversity, fast timeline, no natural pairing, work with any species, and high throughput. Single B Cell provides moderate-high diversity, fast timeline, natural pairing, limited species, and high throughput.

Bispecific Antibody Discovery Services

With extensive experience across major bispecific (BsAb) formats, ProBio offers a one-stop discovery solution from target validation to preclinical candidate (PCC), including format design, construction and expression, functional validation, in vivo studies, and developability assessment.

Overview

Workflow

Case Studies

Related Services

FAQs

Comprehensive Antibody Developability Assessment Platform

Tailored to Your Project

Various bsAb formats compatible with almost any mAb and sdAb sequence, customized bsAb discovery solutions tailored to your target, MOA, and existing antibody candidates.

Integrated Platform

The only partner you need from target to PPC, with early screening and a comprehensive pharmacology platform to streamline workflows.

Proven Experience

Over 110 bsAb discovery projects to date, with the most advanced project in clinical stages and partnership co-development projects activated.

Obtain bsAb Preclinical Candidates in Just 6 Months

Well developed in vitro pharmacology solutions based on different MOAs for bsAbs from discovery to clinic.

Flexible Compatibility

Unmatched format flexibility and superior productivity, supporting diverse bispecific/multispecific architectures. Coupled with rapid, high-yield expression capabilities, we consistently generate high quality, developable candidates within shortened timelines.

Formats include BiTE, CrossMab and KIH, Duobody, IgG-scFv fusions, SMAB, and asymmetric 2+1 designs

In Vitro Bioassay

Four assay platforms, cell‑engager, dual‑target blockade, dual immunomodulator, and cell surface protein‑bridging, designed to assess different biological activities such as immune cell activation, tumor cell killing, pathway inhibition, and signaling modulation.

4 types of bsAb bioassay platforms based on MOA
Over 200 target-overexpressing stable cell lines
Over 10 reporter gene cell lines

In Vivo Pharmacology

Covering PD, PK, and toxicology, we select optimal animal models and develop MOA‑aligned assays to support drug development. With integrated project management and regulatory support, our platform enables faster, higher‑quality, and cost‑efficient outcomes.